Association of Oral Papivir/Pavirona® Supplementation With HPV DNA Clearance

Objective:To evaluate the effects of Papivir/Pavirona® tablets, containing cinnamon extract, selenium, quercetin, licorice root, and green tea extract, on cervical human papillomavirus (HPV) clearance and cytological outcomes in women with cervical HPV infection. Methods: This retrospective cohort study included 239 women with con-firmed cervical HPV infection, followed at a tertiary referral center between February 2023 and August 2025. Participants were classified into a treatment group receiving oral Papivir/Pavirona® twice daily for six months (n = 119) and a control group managed with routine clinical follow-up alone (n = 120). HPV DNA testing and cervical cytology were evaluated at baseline and during follow-up visits at 6 and 12 months. Results: HPV clearance rates were significantly higher among Papivir/Pavirona® users at both 6 and 12 months compared with controls (67.2% vs. 29.2% and 69.1% vs. 46%, respectively). Cytological regression was also more frequent in the Papivir/Pavirona® group at 6 months (81.1% vs. 54.5 %) and 12 months (77.9% vs. 52.8%). In multivariate logistic re-gression analysis, Papivir/Pavirona® use emerged as an independent predictor of both HPV clearance and cytological regression, whereas demographic, reproductive, behav-ioral, and virological baseline characteristics were not significantly associated with outcomes. Conclusions: It has been suggested that Papivir/Pavirona® supplementation is associated with increased HPV clearance and cytological regression rates in women with cervical HPV infection, and may play a potential supportive role in cervical HPV management.